Clinical Trial Results:
"ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITIS REUMATOIDE EN PACIENTES CON UN CONTROL INADECUADO CON METROTEXATO"
"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7
RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF
RHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELY
CONTROLLED ON METHOTREXATE"
Summary
|
|
EudraCT number |
2008-000327-25 |
Trial protocol |
ES CZ PL |
Global completion date |
03 Feb 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Dec 2016
|
First version publication date |
18 Dec 2016
|
Other versions |
|
Summary report(s) |
A6341009 PharmaCM Disclosure Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.